SCHEMBL4014143

SCHEMBL4014143

Clc1ccc(CNc2ccnc(-n3cc4ccccc4n3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.55
KDM4E B2RXH2 1/20 0.48
CLK4 Q9HAZ1 3/20 0.46
DYRK1A Q13627 2/20 0.46
BACE1 P56817 1/20 0.44
GPR39 O43194 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4013492 0.74 MKNK1 (0.62) ACHEKDM4ECLK4DYRK1ABACE1
SCHEMBL14980555 0.71 NPC1 (0.63) KDM4ENPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL8241275 0.71 KDM4E (0.58) ACHEKDM4ECLK4DYRK1ABACE1
SCHEMBL1712561 0.68 ADORA3 (0.54) NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL14980562 0.66 KDM4E (1.00) KDM4EGPR39NPC1RAB9AKMT2A
SCHEMBL29580040 0.66 KDM4E (1.00) KDM4EGPR39NPC1RAB9AKMT2A
Water SCHEMBL4710592 0.66 ADORA3 (0.52) NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4012848 0.66 NPC1 (0.50) KDM4ENPC1RAB9AKMT2A
SCHEMBL1666752 0.65 CYP1A2 (0.64) ACHEKDM4ECLK4KMT2ASMN1; SMN2
SCHEMBL4416090 0.65 BCL6 (0.41) KDM4ENPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US claimed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US claimed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP claimed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO claimed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP disclosed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS KCND2, KCNN3, KCNJ2 ACHE 85/4885KDM4E 2824/4885CLK4 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.